Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study
Primary Purpose
Bladder Cancer
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
immediate urine cytology
Sponsored by
About this trial
This is an interventional diagnostic trial for Bladder Cancer
Eligibility Criteria
Inclusion Criteria:
-patients with primary or recurrent NMIBC for whom complete TURBT was done
Exclusion Criteria:
-Patients with concomitant CIS, upper tract urothelial tumors, biopsy proven muscle invasion, or low risk NMIBC (single, primary, Ta, G1 tumor).
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
NMIBC patients
Arm Description
Patients with primary or recurrent NMIBC for whom complete TURBT was done.
Outcomes
Primary Outcome Measures
Diagnostic performance of IUC
The primary outcome included assessment of the performance of IUC as a predictive tool for possible residual malignancy after primary TURBT. Thereafter, sensitivity (Sn), specificity (Sp), positive and negative predictive values (PPV, NPV) and overall accuracy of IUC as a preliminary step before repeat TURBT will be determined.
Secondary Outcome Measures
The secondary outcome included the evaluation of predictive capacity of IUC for tumor recurrence in the study participants.
The secondary outcome included the evaluation of predictive capacity of IUC for tumor recurrence in the study participants.
Full Information
NCT ID
NCT04194112
First Posted
December 7, 2019
Last Updated
December 11, 2019
Sponsor
Mansoura University
1. Study Identification
Unique Protocol Identification Number
NCT04194112
Brief Title
Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study
Official Title
Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study
Study Type
Interventional
2. Study Status
Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
April 1, 2015 (Actual)
Primary Completion Date
August 1, 2019 (Actual)
Study Completion Date
September 1, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mansoura University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The current study aimed at prospectively assessing the performance of IUC as a predictive tool for residual tumor after primary TURBT of NMIBC, and possible future recurrence.
Detailed Description
The current study aimed at prospectively assessing the performance of IUC as a predictive tool for residual tumor after primary TURBT of NMIBC, and possible future recurrence.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
198 (Actual)
8. Arms, Groups, and Interventions
Arm Title
NMIBC patients
Arm Type
Other
Arm Description
Patients with primary or recurrent NMIBC for whom complete TURBT was done.
Intervention Type
Diagnostic Test
Intervention Name(s)
immediate urine cytology
Intervention Description
Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
Primary Outcome Measure Information:
Title
Diagnostic performance of IUC
Description
The primary outcome included assessment of the performance of IUC as a predictive tool for possible residual malignancy after primary TURBT. Thereafter, sensitivity (Sn), specificity (Sp), positive and negative predictive values (PPV, NPV) and overall accuracy of IUC as a preliminary step before repeat TURBT will be determined.
Time Frame
It was assessed 48 hours after primary TURBT
Secondary Outcome Measure Information:
Title
The secondary outcome included the evaluation of predictive capacity of IUC for tumor recurrence in the study participants.
Description
The secondary outcome included the evaluation of predictive capacity of IUC for tumor recurrence in the study participants.
Time Frame
Within duration of follow up (4 years )
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
-patients with primary or recurrent NMIBC for whom complete TURBT was done
Exclusion Criteria:
-Patients with concomitant CIS, upper tract urothelial tumors, biopsy proven muscle invasion, or low risk NMIBC (single, primary, Ta, G1 tumor).
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study
We'll reach out to this number within 24 hrs